While eculizumab and ravulizumab are also indicated for atypical hemolytic uremic syndrome (aHUS), pegcetacoplan is approved for patients with PNH who remain anemic despite C5 inhibitor therapy. Here, C5 is linked to atypical hemolytic-uremic syndrome.